<DOC>
	<DOCNO>NCT01056744</DOCNO>
	<brief_summary>Background : Safety concern regard use drug elute stent system ( DES ) relate mostly late stent thrombosis , facilitate incomplete stent endothelial coverage . Specific information time course amount endothelial strut coverage different DES require , order refine concept antiplatelet therapy DES implantation . Optical coherence tomography ( OCT ) emerge new gold standard endovascular imaging stent , atherosclerosis progression , vulnerable plaque neointimal proliferation . Very limited OCT data endothelial coverage DES currently available . Aim study comparative evaluation XIENCE V® everolimus elute stent ( Abbot Vascular ) bare metal stent ( BMS ) Coroflex® Blue postdilated drug-eluting balloon ( DEB ) SeQuent® Please ( paclitaxel-eluting balloon , B. Braun Melsungen AG ) term endothelial coverage neointimal proliferation use OCT. Study Design : A number 80 patient schedule elective percutaneous coronary intervention ( PCI ) native coronary stenosis suitable DES implantation OCT image openly randomize 1:1 either XIENCE V® Coroflex® Blue/Sequent® Please . The study prospectively conduct university high-volume PCI center OCT expertise ( Jena , Germany ) . Angiographic follow-up OCT image motorize pull-back 1 mm/s plan patient 6 month implantation study stent . OCT endpoint : ( 1 ) endothelial coverage , express % strut without coverage % stent length contain non-covered strut , respectively ( 2 ) neointimal proliferation , give % neointimal volumetric proliferation within whole stent also focal peak % neointimal area proliferation . The study power clinical endpoint , : subacute late stent thrombosis need revascularization stent segment . Given high number measurement ( 15 cross-section image / 1 mm stent length ) , OCT endpoints likely reach significance level P &lt; 0.05 even follow-up drop-out rate 20 % .</brief_summary>
	<brief_title>Optical Coherence Tomography Evaluate Paclitaxel-Eluting Balloons Everolimus-Eluting Coronary Stents</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Established indication PCI accord guideline American Heart Association American College Cardiology Age &gt; 18 year , write consent Native coronary lesion suitable stent placement OCT image 1 . General exclusion criterion : Pregnancy breast feed mother Comorbidity estimate life expectancy &lt; 50 % 1 year Scheduled major surgery next 6 month Not able give inform write consent noncompliance Participation PCI trial 2 . Procedural exclusion criterion : Acute coronary syndrome cardiogenic shock Previous subacute late coronary stent thrombosis Known nonresponsiveness / allergy aspirin thienopyridines Known allergy everolimus taxol derivates 3 . Angiographic exclusion criterion : Culprit lesion within proximal 10 mm right leave coronary artery Saphenous vein graft Estimated stent length &gt; 30 mm</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>coronary stent</keyword>
	<keyword>optical coherence tomography</keyword>
	<keyword>drug-eluting</keyword>
	<keyword>neointimal proliferation</keyword>
</DOC>